Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add more filters










Publication year range
2.
Ophthalmology ; 107(12): 2215-9, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11097599

ABSTRACT

OBJECTIVE: To report the clinical findings and management of spontaneous hemorrhage in an unsuspected intraorbital arteriovenous malformation. DESIGN: Interventional case report. METHODS: Review of clinical findings, radiologic studies, and treatment of the patient. RESULTS: A 75-year-old woman sought treatment for the rapid onset of severe proptosis. Orbital exploration of a "mass" imaged on computed tomography scan and magnetic resonance imaging resulted in massive intraoperative hemorrhage. Subsequent arteriographic and histopathologic analysis confirmed an underlying orbital arteriovenous malformation. CONCLUSIONS: Spontaneous intraorbital hemorrhage from an arteriovenous malformation is extremely rare, but should be considered in the differential diagnosis of rapidly progressive proptosis.


Subject(s)
Arteriovenous Malformations/complications , Ophthalmic Artery/abnormalities , Orbit/blood supply , Retrobulbar Hemorrhage/etiology , Aged , Arteriovenous Malformations/diagnosis , Arteriovenous Malformations/surgery , Diagnosis, Differential , Exophthalmos/diagnosis , Exophthalmos/etiology , Eye Enucleation , Female , Humans , Magnetic Resonance Imaging , Retrobulbar Hemorrhage/diagnosis , Retrobulbar Hemorrhage/surgery , Tomography, X-Ray Computed , Veins/abnormalities , Visual Acuity
3.
Appl Immunohistochem Mol Morphol ; 8(3): 189-94, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10981870

ABSTRACT

Thyroid transcription factor-1 (TTF-1), a member of the NKx2 family of homeodomain transcription factors, is a mediator of thyroid-specific transcription of the thyroglobulin (TG) gene. The combined immunohistochemical profile of TTF-1, TG, cytokeratin 7 (CK7), and cytokeratin 20 (CK20) in neoplasms of the thyroid gland and their metastases to other sites has not been defined previously. Formalin-fixed tissue of 43 thyroid tumors, including 31 carcinomas and 12 adenomas, and 16 metastasic lesions were immunostained using monoclonal antibodies to TTF-1, TG, CK7, and CK20. Immunoreactivity of the primary tumors (adenomas and carcinomas) for TTF-1 was seen in 32 cases (74%), TG 32 (74%), and CK7 34 (79%), whereas none (0%) showed positivity for CK20. The distribution of reactivity in the 31 carcinomas for TTF-1, TG, and CK7, respectively was papillary (8/8), (8/8), and (8/8); poorly differentiated (6/7), (4/7), and (6/7); oncocytic (Hürthle) cell (2/6), (6/6), and (4/6); follicular (4/4), (3/4), and (3/4); medullary (1/2), (0/2), and (1/2). One of four anaplastic carcinomas was focally immunoreactive showing positivity for TTF-1 only. Of the six follicular adenomas, five were positive for TTF-1, six for TG, and six for CK7. Among the six oncocytic cell adenomas, five were reactive for TTF-1, five for TG, and all six for CK7. Twelve (75%) of the 16 metastatic tumors were positive for TTF-1, 10 (63%) for TG, 15 (94%) for CK7, and none (0%) for CK20. In summary, TTF-1 and TG are demonstrable by immunohistochemistry in the majority of thyroid neoplasms. Compared with TG, an antibody to TTF-I is a similarly sensitive marker for thyroid tumors. Moreover, TTF-1 is a more sensitive marker for poorly differentiated carcinomas and metastasis. In most cases, its nuclear pattern of immunoreactivity facilitates interpretation. Thyroid tumors are CK7+/CK20-. The panel of antibodies for TG, TTF-1, CK7, and CK20 is useful when the thyroid origin of a metastatic tumor is a consideration.


Subject(s)
Adenoma/metabolism , Carcinoma/metabolism , Keratins/biosynthesis , Nuclear Proteins/biosynthesis , Thyroglobulin/biosynthesis , Thyroid Neoplasms/metabolism , Transcription Factors/biosynthesis , Adenoma/pathology , Carcinoma/pathology , Humans , Immunohistochemistry , Thyroid Neoplasms/pathology , Thyroid Nuclear Factor 1
4.
Laryngoscope ; 110(8): 1262-5, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10942123

ABSTRACT

OBJECTIVES: Hyams proposed a histological grading system for esthesioneuroblastoma in which grade I tumors have an excellent prognosis and grade IV tumors are uniformly fatal. The Hyams grading system predated advanced craniofacial techniques, extensive use of immunohistochemistry, and the recognition of sinonasal undifferentiated carcinoma (SNUC) as a distinct entity. Therefore we aimed to determine whether Hyams classification is useful in predicting outcome for esthesioneuroblastoma and SNUC. STUDY DESIGN: A retrospective review of cases from 1970 to 1999. METHODS: Twenty-six patients (12 with esthesioneuroblastoma and 14 with SNUC) were reviewed. The Kadish clinical stage was determined, and histopathological slides were reviewed and graded using the Hyams system. RESULTS: Kadish staging was available for 26 patients (2 patients with stage A tumors; 7 with stage B; and 17 with stage C). Of the 8 evaluable patients with Kadish stage A or B tumors, 6 remained disease free for more than 2 years compared with only 5 of the 17 Kadish stage C tumors. Slides were available for Hyams grading in 21 patients (2 patients with grade I tumors; 4 with grade II; 4 with grade III; and 11 with grade IV). Of the 6 patients with Hyams grade I or II tumors, 4 remained disease free for more than 2 years compared with only 4 of the 15 patients with Hyams grade III or IV tumors. Of note, three patients with Kadish stage C tumors (two with esthesioneuroblastoma, one with SNUC) and two patients with Hyams grade IV tumors (one with esthesioneuroblastoma and one with SNUC) survived for more than 5 years. CONCLUSIONS: Both the Hyams grading system and the Kadish staging system can be used as independent predictors of outcome. Although limited by small numbers, the results of this study demonstrate that patients with either advanced clinical stage or pathological grade of esthesioneuroblastoma or SNUC have poor prognosis, but that long-term survival is possible in these patients if aggressive treatment is used.


Subject(s)
Esthesioneuroblastoma, Olfactory/mortality , Esthesioneuroblastoma, Olfactory/pathology , Nasal Cavity , Nose Neoplasms/mortality , Nose Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Esthesioneuroblastoma, Olfactory/classification , Esthesioneuroblastoma, Olfactory/surgery , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Nose Neoplasms/classification , Nose Neoplasms/surgery , Prognosis , Retrospective Studies , Survival Analysis
5.
Arch Otolaryngol Head Neck Surg ; 124(10): 1097-104, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9776187

ABSTRACT

OBJECTIVE: To determine the safety and efficacy of an immunogenic gene therapy using a drug designed to produce expression of a foreign class I major histocompatibility complex protein in patients with head and neck cancer. DESIGN: Phase 1 prospective clinical trial. SETTING: Academic medical setting. PATIENTS: Nine patients with advanced head and neck squamous cell carcinoma who had failed conventional therapy and did not express HLA-B7, a class I major histocompatibility complex protein. INTERVENTION: Patients were treated with Allovectin-7 (Vical Inc, San Diego, Calif) by direct intratumoral injection. Allovectin-7 contains a plasmid complementary DNA complexed with a cationic lipid, which results in expression of HLA-B7. MAIN OUTCOME MEASURES: Patients were assessed for any toxic effects and for any change in tumor volume. Biopsy specimens obtained before and after therapy were evaluated by immunohistochemistry to detect HLA-B7 expression and with the terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) assay to detect any induction of apoptosis. RESULTS: There were no toxic effects of the gene therapy. In 4 of these 9 patients there was a partial response to treatment, evidenced by a gradual reduction in tumor size. One patient has remained alive for more than 17 months since commencing treatment, with no clinical evidence of disease but with persistent histological evidence of cancer. Analysis of the biopsy specimens from 2 of the patients who responded to therapy demonstrated HLA-B7 expression. The TUNEL assay demonstrated extensive apoptosis in both of these patients, suggesting that this may be the mechanism of tumor reduction. CONCLUSIONS: These data demonstrate the potential efficacy and lack of toxicity of this form of alloantigen gene therapy. A multi-institutional study has been initiated to expand on these findings.


Subject(s)
Carcinoma, Squamous Cell/therapy , DNA , Genetic Therapy/methods , HLA-B7 Antigen/therapeutic use , Head and Neck Neoplasms/therapy , Lipids/therapeutic use , Plasmids/therapeutic use , Adult , Aged , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/mortality , Combined Modality Therapy , DNA, Recombinant , Female , Genetic Therapy/adverse effects , HLA-B7 Antigen/adverse effects , Head and Neck Neoplasms/immunology , Head and Neck Neoplasms/mortality , Histocompatibility Testing , Humans , Immunohistochemistry , Lipids/adverse effects , Male , Middle Aged , Patient Selection , Plasmids/adverse effects , Prospective Studies
6.
Head Neck ; 19(4): 276-80, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9213105

ABSTRACT

BACKGROUND: Tumor angiogenesis has been shown to correlate with tumor size, metastatic potential, and prognosis in breast and other cancers. Studies in head and neck cancer have suggested a similar correlation, but results have been inconclusive. This study was performed to determine the correlation between angiogenesis and oral tumor behavior. METHODS: Tumor angiogenesis was evaluated in 31 T2-T4 primary oral cavity squamous cell carcinomas by quantitating the microvessel density with two different anti-endothelial cell antigens, factor VIII antigen (FVIIIAg) and CD-31. The stains were compared to assess whether these antigens yielded complimentary results. The microvessel densities were correlated with T stage and N stage and patient survival. RESULTS: FVIIIAg and CD-31 staining yielded consistent microvessel densities, but FVIIIAg was generally more uniform and easier to interpret. Increasing microvessel density was seen with increasing T stage and N stage; however, there was considerable overlap and no correlation with survival. CONCLUSIONS: These results suggest that oral tumors are less angiogenesis dependent than tumors in other sites. Tumor angiogenesis, as currently measured, is not of value in predicting tumor aggressiveness in patients with oral cavity carcinoma.


Subject(s)
Carcinoma, Squamous Cell/blood supply , Mouth Neoplasms/blood supply , Neovascularization, Pathologic/pathology , Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Factor VIII/analysis , Female , Humans , Immunohistochemistry , Lymphatic Metastasis , Male , Mouth Neoplasms/mortality , Mouth Neoplasms/pathology , Neoplasm Staging , Platelet Endothelial Cell Adhesion Molecule-1/analysis , Prognosis , Survival Rate , Tongue Neoplasms/blood supply , Tongue Neoplasms/mortality , Tongue Neoplasms/pathology
8.
Laryngoscope ; 106(11): 1378-81, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8914904

ABSTRACT

Inactivation of tumor suppressor genes, including p53 and retinoblastoma (Rb), are commonly found in all cancers, including head and neck squamous cell carcinoma. Alterations at either p53 or Rb, however, are only weakly associated with tumor aggressiveness. In many cancers loss of heterozygosity (LOH) at multiple loci is associated with decreased survival. The polymerase chain reaction and highly informative microsatellite markers were used to compare DNA from matched sets of 63 head and neck squamous cell cancers and normal tissue for LOH at the p53 and Rb loci. At p53, 50 were informative, with LOH occurring in 19 (38%). Of the 57 that were informative at Rb, LOH occurred in 21 (37%). Of the 46 that were informative at both p53 and Rb, LOH occurred in 10 (22%) at both loci. When LOH for p53 and Rb individually was compared to stage, differentiation, and survival, there was no correlation. However, the patients with LOH at both loci had a significantly poorer survival (P = .009). This strongly supports the contention that simultaneous alterations of these two tumor suppressor genes favor tumor aggressiveness and can be used as a prognostic indicator.


Subject(s)
Carcinoma, Squamous Cell/genetics , Genes, Retinoblastoma/genetics , Genes, p53/genetics , Head and Neck Neoplasms/genetics , Carcinoma, Squamous Cell/mortality , DNA, Neoplasm/genetics , Female , Head and Neck Neoplasms/mortality , Heterozygote , Humans , Male , Middle Aged , Polymerase Chain Reaction , Prognosis , Survival Analysis
9.
Head Neck ; 18(4): 343-6, 1996.
Article in English | MEDLINE | ID: mdl-8780945

ABSTRACT

BACKGROUND: Angiogenesis is necessary for tumor growth and metastasis. In breast and other cancers angiogenesis has been shown to correlate with tumor size, metastatic potential, and prognosis. Some studies of head and neck cancer have shown a similar correlation, although results are inconclusive. This study was performed to determine whether tumor angiogenesis can be used as a prognostic indicator for early oral cancers. METHODS: CD-31 immunostaining, the technique of choice for determining microvessel density, was utilized to investigate T1 squamous cell carcinomas of the ventral tongue and floor of the mouth. RESULTS: Adequate staining was achieved in 19 tumors. Seven tumors were deemed aggressive due to either the development of metastases or recurrence. The mean microvessel density in the aggressive patients was 43.1/hpf (range 15--79) and in the nonaggressive patients was 38.6/hpf (range 17--78). Statistical analysis failed to reveal any correlation between tumor aggressiveness and tumor angiogenesis in these early tumors. CONCLUSIONS: Tumor angiogenesis failed to predict tumor aggressiveness in T1 oral cavity carcinoma; however, low levels of neoangiogenesis were seen in all cases. For this reason this technique may prove more valuable in more advanced cancers.


Subject(s)
Carcinoma, Squamous Cell/blood supply , Mouth Neoplasms/blood supply , Neovascularization, Pathologic , Adult , Aged , Antigens, CD , Carcinoma, Squamous Cell/pathology , Female , Humans , Male , Middle Aged , Mouth Neoplasms/pathology , Neoplasm Staging , Prognosis , Statistics, Nonparametric
10.
Arch Otolaryngol Head Neck Surg ; 122(5): 517-9, 1996 May.
Article in English | MEDLINE | ID: mdl-8615969

ABSTRACT

OBJECTIVE: To determine the efficacy of toluidine blue in assessing margin status after removal of squamous cell carcinomas of the upper aerodigestive tract. DESIGN: A prospective study of 50 consecutive patients undergoing surgical resection of squamous cell carcinomas of the upper aerodigestive tract was performed during February 1 to December 1, 1993. After tumor resection, toluidine blue was applied directly to the remaining unresected mucosa. The staining characteristics of the mucosa were then compared with those of frozen-section biopsy specimens of the margins and with the permanent histologic findings of the resected tumor specimen. RESULTS: In three cases, toluidine blue identified a positive margin, which was confirmed on frozen and permanent section. In six cases, false-positive staining was noted, which was most frequently related to traumatic handling of the mucosa during the resection. In no case was a positive margin found on histologic staining that failed to stain with toluidine blue. During routine staining of surrounding unresected mucosa, three cases of a second primary tumor that was not seen on routine evaluation before tumor removal were identified with toluidine blue. In one case, a second T1 oral cavity lesion was found, while in the other cases, separate pharyngeal lesions were identified. CONCLUSION: Based on these findings, it appears that toluidine blue improved the ability to assess margin status at the time of resection, and we advocate its use after resection of tumors to the upper aerodigestive tract.


Subject(s)
Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/surgery , Hypopharyngeal Neoplasms/diagnosis , Hypopharyngeal Neoplasms/surgery , Hypopharynx/surgery , Oropharyngeal Neoplasms/diagnosis , Oropharyngeal Neoplasms/surgery , Oropharynx/surgery , Tolonium Chloride , Carcinoma, Squamous Cell/pathology , Humans , Hypopharyngeal Neoplasms/pathology , Hypopharynx/pathology , Oropharyngeal Neoplasms/pathology , Oropharynx/pathology , Prospective Studies , Retrospective Studies
11.
Mod Pathol ; 9(4): 445-52, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8729987

ABSTRACT

Antibodies to the pulmonary epithelial cell-specific proteins surfactant proteins A and B (SP-A and SP-B) and to thyroid transcription factor-1 (TTF-1), a homeodomain nuclear transcription protein, were used as immunohistochemical markers to asses their ability to distinguish primary pulmonary non-small cell carcinomas (n = 57) from carcinomas of the breast (n = 51). SP-A, SP-B, and TTF-1 were detected in 49%, 53%, and 63% of non-small cell carcinomas, respectively. These three antibodies stained pulmonary adenocarcinomas in 54%, 63% and 76% of specimens, respectively. Squamous cell carcinomas rarely stained using these markers. Antibodies to SP-B and TTF-1 never stained any of the 51 breast carcinomas, whereas four of these tumors stained for SP-A. To better define the potential diagnostic value of these antibodies, 13 breast carcinomas metastatic to the lung were studied. Of the three antibodies tested, only TTF-1 seemed useful, because none of the 13 metastatic tumors showed immunoreactivity to this antibody, whereas six specimens (46%) showed reactivity for both SP-A and SP-B. To emphasize further the potential usefulness of antibodies to TTF-1, sections of adenocarcinomas of the colon (n = 18) and prostate (n = 9), renal cell carcinomas (n = 8), and epithelioid mesotheliomas (n = 4) were evaluated; none was positive. Only one of 66 gastric and one of eight endometrial adenocarcinomas showed focal positivity. These results demonstrate the usefulness of immunodetection of a pulmonary cell selective transcription protein (TTF-1) in the diagnosis of pulmonary adenocarcinoma, readily distinguishing breast carcinomas from primary pulmonary adenocarcinomas. In contrast, staining for SP-A and SP-B is of limited value, because there is an unacceptably high rate of cross-reactivity between breast carcinomas metastatic to the lung and primary pulmonary carcinomas. The latter finding illustrates and supports the fact that tumor marker phenotypes might differ in primary and secondary tissue sites.


Subject(s)
Adenocarcinoma/chemistry , Adenocarcinoma/pathology , Breast Neoplasms/chemistry , Breast Neoplasms/pathology , Carcinoma, Non-Small-Cell Lung/chemistry , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/chemistry , Lung Neoplasms/pathology , Nuclear Proteins/analysis , Proteolipids/analysis , Pulmonary Surfactants/analysis , Thyroid Gland/metabolism , Transcription Factors/analysis , Biomarkers, Tumor/analysis , Diagnosis, Differential , Humans , Immune Sera , Immunohistochemistry , Lung Neoplasms/secondary , Pulmonary Surfactant-Associated Protein A , Pulmonary Surfactant-Associated Proteins , Thyroid Nuclear Factor 1
12.
AJNR Am J Neuroradiol ; 16(4 Suppl): 916-8, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7611073

ABSTRACT

We described a patient with a pulsatile retroauricular mass that was caused by pathologically proved angiolymphoid hyperplasia with eosinophilia. Angiography and contrast-enhanced CT were performed before surgical excision. Although rare, this entity should be considered in the differential diagnosis of hypervascular masses of the superficial head and neck.


Subject(s)
Angiolymphoid Hyperplasia with Eosinophilia/diagnostic imaging , Cerebral Angiography , Tomography, X-Ray Computed , Adult , Angiolymphoid Hyperplasia with Eosinophilia/pathology , Angiolymphoid Hyperplasia with Eosinophilia/surgery , Diagnosis, Differential , Female , Humans , Muscle, Smooth, Vascular/pathology , Neck/blood supply
15.
J Clin Oncol ; 10(11): 1674-81, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1403050

ABSTRACT

PURPOSE: To characterize the clinical and pathologic features of patients who developed breast cancer (BC) after treatment for Hodgkin's disease (HD). Recent epidemiologic studies have shown that women who are cured of HD have an increased risk of developing BC. PATIENTS AND METHODS: The clinical data, mammograms, and pathologic specimens of 37 women who developed 45 BCs (eight bilateral events), and had a prior history of treatment for HD were analyzed. RESULTS: The median age at diagnosis of HD was 27 years (range, 11 to 60). All patients received radiotherapy (RT) to the upper part of their body, and 10 also had chemotherapy for HD. The median interval from the treatment of HD to the diagnosis of BC was 15 years (range, 8 to 34). The median age at diagnosis of BC was 43 years (range, 27 to 75), 41% of patients were 39 years old or younger. Most mammograms (81%) showed abnormal findings of mass and/or microcalcifications. Of the eight patients (22%) with bilateral tumors, four were synchronous and four were metachronous. Involvement of the medial half of the breast occurred more frequently than in patients with primary BC (39% and 21%, respectively; P < .002). But, the histologic types, grades, presence of lymphocytic reaction, and lymphatic invasion were similar to those observed in 935 primary BC patients who were previously analyzed at our center. The 6-year actuarial relapse-free survival (RFS) for node-negative BC after HD was 85%. Node-positive patients had a significantly lower RFS of 33% (P = .002). CONCLUSIONS: In comparison to patients with primary BC, patients who develop BC after HD are more likely to be younger, have bilateral disease, and have their tumors more frequently involve the medial half of the breast. Pathologic characteristics, nodal involvement, and prognosis are similar to those of primary BC. BC in women who were treated for HD is becoming an increasing problem, as more patients cured of HD reach a follow-up time of 10 to 15 years. Breast examination and mammography at an early age should be part of the follow-up program for women who are cured of HD.


Subject(s)
Breast Neoplasms/pathology , Carcinoma/pathology , Hodgkin Disease/radiotherapy , Neoplasms, Radiation-Induced/pathology , Neoplasms, Second Primary/pathology , Adolescent , Adult , Breast Neoplasms/etiology , Carcinoma/etiology , Child , Female , Humans , Middle Aged , Neoplasms, Radiation-Induced/etiology , Neoplasms, Second Primary/etiology , Radiotherapy/adverse effects , Survival Analysis
17.
Otolaryngol Head Neck Surg ; 106(3): 296-301, 1992 Mar.
Article in English | MEDLINE | ID: mdl-1317031

ABSTRACT

CMV is the most important viral opportunist in patients with AIDS. Nearly all patients with AIDS have been exposed to CMV and the virus can be isolated from many. When CMV-related disease occurs in AIDS, it has usually involved the eye or gastrointestinal tract. In lesions in which CMV is the suspected etiology, evidence of direct pathogenicity of the virus should be obtained, usually histologically. Accurate diagnosis is essential because long-term therapy with a relatively toxic drug (ganciclovir) is indicated. We have presented a case of CMV infection of the larynx that responded, albeit slowly, to ganciclovir. Additional cases may arise as the prevalence of AIDS increases. Because of the potential for airway compromise and the tendency toward chronicity, CMV infection of the larynx should be of a significant concern both for the patient and the otolaryngologist.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Cytomegalovirus Infections , Laryngeal Diseases/microbiology , Adult , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/pathology , Diagnosis, Differential , Ganciclovir/administration & dosage , Homosexuality , Humans , Laryngeal Diseases/drug therapy , Laryngeal Diseases/pathology , Male
18.
Head Neck ; 14(1): 49-54, 1992.
Article in English | MEDLINE | ID: mdl-1624293

ABSTRACT

Tumors arising in the parapharyngeal space are rare. Even more rare are those which originate from the pharyngeal and parapharyngeal musculature. Three examples of muscle tumors presenting as parapharyngeal masses are reported, ie, a rhabdomyoma, rhabdomyosarcoma, and a leiomyosarcoma, and the literature pertaining to these tumors is reviewed. To the best of our knowledge, this represents the first case of a parapharyngeal leiomyosarcoma reported in the literature.


Subject(s)
Leiomyosarcoma/diagnosis , Pharyngeal Neoplasms/diagnosis , Rhabdomyoma/diagnosis , Rhabdomyosarcoma/diagnosis , Adult , Aged , Child, Preschool , Female , Humans , Leiomyosarcoma/diagnostic imaging , Leiomyosarcoma/pathology , Male , Pharyngeal Neoplasms/diagnostic imaging , Pharyngeal Neoplasms/pathology , Rhabdomyoma/diagnostic imaging , Rhabdomyoma/pathology , Rhabdomyosarcoma/diagnostic imaging , Rhabdomyosarcoma/pathology , Skull/diagnostic imaging , Tomography, X-Ray Computed
19.
Am J Surg Pathol ; 15(6): 599-604, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1674409

ABSTRACT

A 58-year-old euthyroid man with episodic flushing and a 2-year history of progressive wheezing was found to have a hypoechoic lesion in one lobe of his thyroid and hypercalcitoninemia in response to pentagastrin stimulation. Thyroidectomy revealed bilateral C-cell hyperplasia unexpectedly associated with chronic lymphocytic thyroiditis. The C-cells exhibited positive immunohistochemical staining for calcitonin and polyclonal carcinoembryonic antigen (CEA). Postoperatively, the wheezing and flushing subsided and the serum calcitonin level was not elevated with pentagastrin stimulation. The substance or substances responsible for the wheezing and flushing were not specifically identified. Nine other specimens of chronic lymphocytic thyroiditis were examined for C-cell hyperplasia and two had small hyperplastic foci, but of a lesser degree than the index case. These patients did not exhibit wheezing and flushing. The development of C-cell hyperplasia in chronic lymphocytic thyroiditis is uncommon and the mechanism for its occurrence is unexplained. This patient appears to be the first reported case of symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis. The substance or substances responsible for the clinical symptoms remain to be identified.


Subject(s)
Carcinoma/pathology , Thyroid Gland/pathology , Thyroid Neoplasms/pathology , Thyroiditis, Autoimmune/pathology , Acute Disease , Calcitonin/metabolism , Carcinoembryonic Antigen/metabolism , Carcinoma/complications , Humans , Hyperplasia , Immunohistochemistry , Male , Middle Aged , Multiple Endocrine Neoplasia/pathology , Pentagastrin/pharmacology , Respiratory Sounds , Thyroid Gland/metabolism , Thyroid Neoplasms/complications , Thyroiditis, Autoimmune/complications , Thyroiditis, Autoimmune/metabolism
20.
Am J Clin Pathol ; 93(4): 510-5, 1990 Apr.
Article in English | MEDLINE | ID: mdl-2321582

ABSTRACT

A new model of invasive pulmonary aspergillosis (IPA) was developed in immunosuppressed mice. Intranasal route of inoculation was used to deliver predictable numbers of Aspergillus flavus conidia. The LD50 was determined to be 2.7 X 10(2) viable conidia, and a combination of quantitative culture and determination of chitin content was shown to best measure the progression of pulmonary disease. The evolution of IPA in these mice conformed with what has been reported in human cases of aspergillosis; both histopathology of the pulmonary lesions and dissemination pattern resembled their human counterparts. The authors hope to use this model to study virulence mechanisms of Aspergillus and novel therapeutic methods.


Subject(s)
Aspergillosis/pathology , Lung Diseases, Fungal/pathology , Administration, Intranasal , Animals , Aspergillosis/microbiology , Brain/microbiology , Brain/pathology , Disease Models, Animal , Female , Kidney/microbiology , Kidney/pathology , Lethal Dose 50 , Liver/microbiology , Liver/pathology , Lung/microbiology , Lung/pathology , Lung Diseases, Fungal/microbiology , Mice
SELECTION OF CITATIONS
SEARCH DETAIL
...